GENE ONLINE|News &
Opinion
Blog

2022-03-08| Special

From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses

by GeneOnline
Share To
More than 30% of adults worldwide have experienced generalized anxiety disorder and 5% suffer from depression, not including the population with other mental illnesses such as attention deficit hyperactivity disorder (ADHD) or post-traumatic stress disorder (PTSD).

Based on statistics, the estimated revenue of the U.S. mental health market was $397.4 billion and the global market size is expected to grow to more than $500 billion by 2030.
The market growth has brought about the rise of novel treatments. Psychedelics, a family of highly controversial drugs, are being gradually destigmatized and attracting attention from scientists and investors. What are the most common psychedelics? 

GO Prime with only $1.49 now

LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top